Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

被引:50
作者
Allarakhia, Minna [1 ]
机构
[1] Univ Waterloo, Dept Management Sci, Waterloo, ON N2L 3G1, Canada
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2013年 / 7卷
关键词
repurposing; open source; rare diseases; neglected tropical diseases; models of collaboration; human-capacity development; FDA-APPROVED DRUGS; DISCOVERY; TUBERCULOSIS; DATABASE; RARE;
D O I
10.2147/DDDT.S46289
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. In the case of neglected tropical diseases, it is suggested that the development of human capital be a central aspect of drug-repurposing programs. Open-source models can support human-capital development through collaborative data generation, open compound access, open and collaborative screening, preclinical and possibly clinical studies. Given the urgency of drug development for neglected tropical diseases, the review suggests elements from current repurposing programs be extended to the neglected tropical diseases arena.
引用
收藏
页码:753 / 766
页数:14
相关论文
共 60 条
  • [51] Oral miltefosine for the treatment of Indian visceral leishmaniasis
    Sundar, Shyam
    Jha, T. K.
    Thakur, C. P.
    Bhattacharya, S. K.
    Rai, M.
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2006, 100 : S26 - S33
  • [52] Rare diseases, orphan drugs and their regulation: questions and misconceptions
    Tambuyzer, Erik
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (12) : 921 - 929
  • [53] Thayer AM, 2012, CHEM ENG NEWS, V90, P15
  • [54] PROMISCUOUS: a database for network-based drug-repositioning
    von Eichborn, Joachim
    Murgueitio, Manuela S.
    Dunkel, Mathias
    Koerner, Soeren
    Bourne, Philip E.
    Preissner, Robert
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 : D1060 - D1066
  • [55] Repurposing Approved and Abandoned Drugs for the Treatment and Prevention of Cancer through Public-Private Partnership
    Weir, Scott J.
    DeGennaro, Louis J.
    Austin, Christopher P.
    [J]. CANCER RESEARCH, 2012, 72 (05) : 1055 - 1058
  • [56] The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
    Wellman-Labadie, Olivier
    Zhou, Youwen
    [J]. HEALTH POLICY, 2010, 95 (2-3) : 216 - 228
  • [57] Wu Y, 2001, Afr J Med Med Sci, V30 Suppl, P52
  • [58] Network-based drug repositioning
    Wu, Zikai
    Wang, Yong
    Chen, Luonan
    [J]. MOLECULAR BIOSYSTEMS, 2013, 9 (06) : 1268 - 1281
  • [59] Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases
    Xu, Kui
    Cote, Timothy R.
    [J]. BRIEFINGS IN BIOINFORMATICS, 2011, 12 (04) : 341 - 345
  • [60] Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
    Zhu, S
    Stavrovskaya, IG
    Drozda, M
    Kim, BYS
    Ona, V
    Li, MW
    Sarang, S
    Liu, AS
    Hartley, DM
    Du, CW
    Gullans, S
    Ferrante, RJ
    Przedborski, S
    Kristal, BS
    Friedlander, RM
    [J]. NATURE, 2002, 417 (6884) : 74 - 78